LY-4101174 is under development for the treatment of solid tumors, urothelial carcinoma, triple negative breast cancer, non-small cell lung cancer, esophageal cancer, pancreatic c ...
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback